Differential Diagnostic Value of F-FDG PET/CT Imaging in Multiple Myeloma and Bone Metastases.
10.19746/j.cnki.issn.1009-2137.2020.04.031
- Author:
Qing-Zhong ZHENG
1
;
Jie-Min SU
1
;
Xiao-Ling LI
1
;
Zhuang-Jun CHEN
1
;
Sheng-Zhi WANG
1
;
Yong ZENG
2
Author Information
1. Department of Radiology，Hainan West Central Hospital，Danzhou 571799，Hainan Province，China.
2. Department of Radiology，Hainan West Central Hospital，Danzhou 571799，Hainan Province，China,E-mail: zengyong50201@163.com.
- Publication Type:Journal Article
- MeSH:
Fluorodeoxyglucose F18;
Humans;
Multiple Myeloma;
Positron Emission Tomography Computed Tomography;
Positron-Emission Tomography;
Radiopharmaceuticals;
Retrospective Studies;
Tomography, X-Ray Computed
- From:
Journal of Experimental Hematology
2020;28(4):1267-1271
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the imaging characteristics of F-FDG positron emission computed tomography (F-FDG PET/CT) in multiple myeloma (MM) patients and to analyze its application value in MM and bone metastases.
METHODS:A retrospective analysis was made on MM patients (n=72) and bone metastases patients (n=50) admitted to Hainan Western Central Hospital from January 2017 to March 2019. All patients underwent F-FDG PET/CT examination. The distribution of lesions, bone destruction, maximum standardized uptake (SUV) and metabolic homogeneity were analyzed in both groups.
RESULTS:More than 80% of MM and bone metastases involved thoracic bone, spine and pelvis, followed by limbs. MM was more common in the lesions of thoracic bone and skull than those in bone metastases, the difference was statistically significant (P＜0.05). The majority of MM patients presented osteolytic bone destruction (97.2%), mostly showing "insect-like phagocytic pattern", so the bone showed dilated changes, and osteogenic changes were rarely seen (2.8%). Osteolytic bone destruction accounted for 74.0% in patients with bone metastatic tumor, presenting "focal" appearance more often, and osteogenic changes accounted for 26.0%. Osteolytic bone destruction in patients with MM was significantly higher than that in patients with bone metastases（χ=14.757，P＜0.05）. The SUV of MM (4.25±2.16)was significantly lower than that of bone metastases (7.84±3.25) (t=6.830, P＜0.05). Diffuse mild uptake of F-FDG was more common in patients with MM, and heterogeneous high uptake of F-FDG was more common in patients with bone metastasis, the difference was statistically significant (P＜0.05).
CONCLUSION:F-FDG PET/CT examination is helpful to acquire the imaging features of bone structure and metabolic changes, and shows an important clinical value in the differential diagnosis of MM and bone metastases.
